Gender- and disease-specific urinary thioredoxin in chronic kidney disease patients with or without type 2 diabetic nephropathy

被引:5
|
作者
Tobino, Kyoko [1 ,3 ]
Muso, Eri [1 ]
Iwasaki, Yukako [1 ]
Yonemoto, Satomi [1 ,2 ]
Kasuno, Kenji [4 ,5 ]
Tsukamoto, Tatsuo [1 ]
Nakamura, Hajime [2 ]
Tomino, Yasuhiko [3 ]
机构
[1] Kitano Hosp, Tazuke Kofukai Med Res Inst, Div Nephrol & Dialysis, Ctr Nephrol & Urol, Osaka 5308480, Japan
[2] Kitano Hosp, Tazuke Kofukai Med Res Inst, Div Prevent Med, Osaka 5308480, Japan
[3] Juntendo Univ, Fac Med, Dept Internal Med, Div Nephrol, Tokyo, Japan
[4] Univ Fukui Hosp, Div Nephrol, Fukui, Japan
[5] Univ Fukui Hosp, Clin Labs, Fukui, Japan
关键词
chronic kidney disease; diabetic nephropathy; gender; oxidative stress; thioredoxin; OXIDATIVE STRESS; EXPRESSION; PROTEIN; 8-HYDROXYDEOXYGUANOSINE; ACTIVATION; ELEVATION; ROLES; CELLS;
D O I
10.1111/nep.12403
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aim: The role of urinary (U-) thioredoxin (Trx), a class of small redox proteins, in physiological and pathological conditions, in addition to its gender specificity, has been insufficiently determined in chronic kidney disease (CKD) patients, especially in diabetes mellitus (DM) nephropathy. Methods: U-Trx was measured cross-sectionally in 110 CKD outpatients with estimated glomerular filtration rate (eGFR) of >15 mL/min per 1.73 m(2), namely, in 57 type 2 DM patients (male: n = 41, female: n = 16) and 53 non-DM patients (M: n = 33, F: n = 20), as well as 30 healthy controls (M: n = 11, F: n = 19). Comparisons were made among controls, DM and non-DM, and between M and F, with clinical parameters compared in each group. In addition, a comparison between average U-Trx level and the changes of renal function during a one-year period was performed. Results: U-Trx was significantly higher in females than in males in controls (P < 0.05) and in non-DM patients (P < 0.05). Multiple regression analysis revealed that urinary protein (UP)/creatinine (Cr) ratio, female sex and HbA1c were independent factors affecting U-Trx among all subjects (adjusted R-2 = 0.468). In DM patients, U-Trx was negatively correlated with eGFR, especially in males, and positively correlated with UP/Cr and NAG in both sexes (all P < 0.01), as well as with systolic blood pressure in all (P < 0.05). Average U-Trx was positively correlated with the rate of annual eGFR decline of male (P < 0.01) but not female DM patients. Conclusion: U-Trx might have a gender-specific physiological and pathological role and be a potent marker of renal damage in DM nephropathy.
引用
收藏
页码:368 / 374
页数:7
相关论文
共 50 条
  • [21] The Role of Autophagy in Type 2 Diabetic Kidney Disease Management
    Tseng, Che-Hao
    Shah, Kavya M.
    Chiu, I-Jen
    Hsiao, Li-Li
    CELLS, 2023, 12 (23)
  • [22] 24-h Urinary Calcium Excretion and Renal Outcomes in Hospitalized Patients with and without Chronic Kidney Disease
    Guo, Xinru
    Wang, Wanling
    Ma, Yangyang
    Liang, Yanjun
    Zhou, Yena
    Cai, Guangyan
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (14)
  • [23] Association of urinary calcium excretion with chronic kidney disease in patients with type 2 diabetes
    Wang, Yanru
    Chen, Yuxing
    Yu, Yanping
    Pan, Xin
    Fu, Guoxiang
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2024, 56 (08) : 2715 - 2723
  • [24] Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease
    Abe, Masanori
    Maruyama, Noriaki
    Oikawa, Osamu
    Maruyama, Takashi
    Okada, Kazuyoshi
    Soma, Masayoshi
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2015, 75 (05) : 421 - 427
  • [25] Advanced glycation end-products and arterial stiffness in patients with diabetic nephropathy and patients with chronic kidney disease without diabetes
    Strozecki, Pawel
    Kurowski, Robert
    Flisinski, Mariusz
    Stefanska, Anna
    Odrowaz-Sypniewska, Grazyna
    Manitius, Jacek
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2013, 123 (11): : 609 - 616
  • [26] Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease
    Cláudia Nogueira
    Selma B. Souto
    Eduardo Vinha
    Daniel Carvalho-Braga
    Davide Carvalho
    Hormones, 2013, 12 : 483 - 494
  • [27] Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease
    Nogueira, Claudia
    Souto, Selma B.
    Vinha, Eduardo
    Carvalho-Braga, Daniel
    Carvalho, Davide
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2013, 12 (04): : 483 - 494
  • [28] Changes in Trace Elements During Early Stages of Chronic Kidney Disease in Type 2 Diabetic Patients
    Lin, Ching-Chiang
    Shih, Ching-Tang
    Lee, Chien-Hung
    Huang, Yeou-Lih
    BIOLOGICAL TRACE ELEMENT RESEARCH, 2018, 186 (02) : 330 - 336
  • [29] Effect of Tolvaptan in Patients With Chronic Kidney Disease Due to Diabetic Nephropathy With Heart Failure
    Sato, Eiichi
    Nakamura, Tsukasa
    Amaha, Mayuko
    Nomura, Mayumi
    Matsumura, Daisuke
    Yamagishi, Hidetsugu
    Ono, Yuko
    Ueda, Yoshihiko
    INTERNATIONAL HEART JOURNAL, 2014, 55 (06) : 533 - 538
  • [30] Association of urinary acidification function with the progression of diabetic kidney disease in patients with type 2 diabetes
    Zhu, Huanhuan
    Liu, Xi
    Zhang, Chengning
    Li, Qing
    An, Xiaofei
    Liu, Simeng
    Wu, Lin
    Zhang, Bo
    Yuan, Yanggang
    Xing, Changying
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2019, 33 (11)